---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-008123"
form_type: "8-K"
ticker: "ENGN"
cik: "0001980845"
company_name: "enGene Therapeutics Inc."
filed_at: "2024-01-29T23:59:59+00:00"
generated_at: "2026-06-06T16:09:58.795294+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# enGene reports FY2023 net loss $104.7M; Phase 1 LEGEND study 68% CR rate, interim data mid-2024

## Summary
- FY2023 net loss $104.7M ($151.22/share) vs $29.0M ($44.30) in FY2022; operating expenses $26.0M.
- Phase 1 LEGEND study in BCG-unresponsive NMIBC met endpoints; 68% complete response at 3 months (n=22); pivotal Phase 2 enrolling, interim data mid-2024.
- Completed reverse merger with FEAC and upsized PIPE financing, net proceeds ~$109M; launched on Nasdaq Nov 1, 2023.
- Expanded Hercules debt facility to $50M ($22.5M funded); cash $81.5M at Oct 31, 2023, runway into Q2 2025.
- Leadership hires: Alex Nichols (President/COO), Richard Bryce (CMO), Ryan Daws (CFO), Lota Zoth (Board).

## SEC filing metadata
- accession: 0000950170-24-008123
- form_type: 8-K
- ticker: ENGN
- cik: 0001980845
- company_name: enGene Therapeutics Inc.
- filed_at: 2024-01-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1980845/000095017024008123/0000950170-24-008123-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1980845/000095017024008123/engn-20240129.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-008123
- JSON: https://secwatch.observer/filing/0000950170-24-008123.json
- Plain text: https://secwatch.observer/filing/0000950170-24-008123.txt

## Key facts
- Earnings Releases
  enGene Therapeutics Inc. reported the fiscal year ended October 31, 2023 results: net income $104.7 million, EPS $151.22 per share.
  - Period: the fiscal year ended October 31, 2023
  - Net income: $104.7 million
  - EPS: $151.22 per share
  - Result: reported results
  source text: For the full year 2023, net loss attributable to common shareholders was $104.7 million, or $151.22 per share, compared to $29.0 million, or $44.30 per share, for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000095017024008123/0000950170-24-008123-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.